• NFIA Coordinates Bone Remodeling and Mass Accrual

  2026-08-19

  A recent Genes & Diseases study identifies nuclear factor I/A (NFIA) as a context-dependent regulator of bone homeostasis in mesenchymal stem and progenitor cells. By suppressing RANKL-driven osteoclastogenesis while also restraining osteoblast differentiation through SFRP1 and Wnt/β-catenin signaling, NFIA produces a dual but unbalanced effect in which control of bone resorption predominates.

• 4-Ethylphenyl Sulfate Research Workflows

  2026-08-19

  Build more informative renal biomarker, surface adsorption, and gut microbiota-brain interaction assays with 4-ethylphenyl sulfate. This workflow emphasizes matrix-matched controls, toxin-aware biomaterial testing, and practical troubleshooting for reproducible results.

• TNF-alpha Recombinant Murine Protein: A Signaling Lens

  2026-08-18

  Explore how TNF-alpha recombinant murine protein can function as a mechanistic reference for apoptosis, inflammation, and transcriptional-stress studies. This guide connects tumor necrosis factor alpha biology with the RNA Pol II degradation-dependent apoptotic response and translates that distinction into better assay design.

• Genetically Engineered Mouse Models of Mesothelioma

  2026-08-18

  Kadariya and colleagues present a protocol-centered framework for modeling mesothelioma using genetically engineered mice carrying Bap1 alterations and, where appropriate, additional tumor-suppressor defects or asbestos exposure. The work shows how germline, conditional, and autochthonous models can connect mesothelioma genetics with inflammation, tumor development, and preclinical therapeutic testing in immunocompetent animals.

• Amiloride (MK-870) for Ion-Transport Assays

  2026-08-17

  Amiloride (MK-870) is a practical perturbation tool for separating ENaC- and uPAR-associated effects from antigen uptake, trafficking, and presentation. This workflow connects sodium channel research with the ER-targeted immunoliposome strategy reported in a recent vaccine study while clearly distinguishing established findings from assay hypotheses.

• Recombinant Mouse M-CSF: Applied Workflows

  2026-08-17

  Build more reproducible mouse macrophage, osteoclast, cancer, and fibrosis assays with a tag-free M-CSF workflow. This guide connects controlled macrophage differentiation to metabolic and inflammatory readouts inspired by the IGF2BP1–THBS1–TLR4 pulmonary fibrosis axis.

• B-Cell Ether Lipids Shape Germinal Centers

  2026-08-16

  The reference study shows that B-cell-intrinsic PexRAP, encoded by Dhrs7b, supports ether phospholipid production, B-cell survival, germinal center development, and effective antibody maturation. Its combination of inducible genetic models, imaging mass spectrometry, immunization, and mechanistic cell analysis provides a framework for connecting lipid metabolism with humoral immunity.

• Tyrothricin in Reliable Viability Assays

  2026-08-15

  Learn how Tyrothricin (SKU BA1054) can be integrated into viability, cytotoxicity, and infection-model workflows without conflating antimicrobial effects with mammalian cell injury. This scenario-based guide covers controls, membrane-disruption studies, storage, redox-related interpretation, and practical vendor selection.

• Tamoxifen in PINK1–Iron Cancer Models

  2026-08-14

  Tamoxifen is more than a selective estrogen receptor modulator in conditional cancer models: it can determine when and how CreER-mediated gene knockout is interpreted. This article connects tamoxifen experimental design with PINK1-dependent mitochondrial iron biology while separating genetic effects from drug-induced confounding.

• Cy3-UTP and the Spatial Logic of RNA Processing

  2026-08-14

  A mechanistic and translational perspective on how Cy3-UTP can help researchers test RNA localization, nuclear speckle organization, and co-transcriptional processing hypotheses inspired by new findings on Alu repeat-containing RNAs.

• Relative vs Fractional Viability in Cancer Drug Studies

  2026-08-13

  Hannah R. Schwartz’s 2022 dissertation examines why relative viability and fractional viability should not be treated as interchangeable measures of anticancer drug response. Its central finding is that drug-induced growth inhibition and cell death usually occur together, but in different proportions and with distinct timing, providing a stronger framework for interpreting in vitro pharmacology.

• EdU Flow Cytometry Assay Kits (Cy3) for Prostate Cancer

  2026-08-13

  Translate BaP exposure studies into quantitative S-phase, tumor-cell, and immune-cell readouts with a denaturation-free click-chemistry workflow. The Cy3 assay supports multiplexed cell cycle analysis, genotoxicity testing, and pharmacodynamic experiments while preserving antigenicity for marker-based gating.

• SP600125 JNK Inhibitor: Applied Workflows

  2026-08-12

  SP600125 enables time-resolved interrogation of JNK-dependent phosphorylation, apoptosis, and inflammatory signaling. This practical guide connects its established c-Jun and cytokine use cases with assay strategies inspired by recent trigeminal ganglion research, while clearly separating validated evidence from exploratory applications.

• Recombinant Mouse M-CSF: Assay Design Guide

  2026-08-12

  Recombinant Mouse Macrophage Colony Stimulating Factor (M-CSF) can do more than expand macrophages: it can define the cellular baseline for mechanistic studies. This guide connects PM2021 biology with macrophage metabolism and fibrosis assay design while separating differentiation effects from disease-specific signaling.

• Tamoxifen Workflows for CreER and Cancer Research

  2026-08-11

  Explore practical Tamoxifen workflows for temporally controlled CreER-mediated gene knockout, breast cancer research, and signaling assays. This guide also translates a SERM antimalarial study into hypothesis-driven assay design while emphasizing solubility control, appropriate comparators, and reproducible troubleshooting.

545 records 7/37 page Previous Next First page 上5页 678910 下5页 Last page